Navigation Links
Statin Users Suffering from Side Effects Are in the Dark
Date:5/7/2012

PASADENA, Texas, May 7, 2012 /PRNewswire/ -- Experts estimate nearly 30 million Americans, approximately 10 percent of the population, take some form of cholesterol-lowering drug, also known as statins, under brands such as Lipitor®, Zocor®, Pravachol®, and Crestor®. Statins are among the most widely prescribed drugs in the United States and cardiologists agree that they remain the most effective long-term treatment for cholesterol patients in the high-risk category. However, many patients are not aware that through regular statin therapy they may be depleting their bodies of valuable vitamins and nutrients essential for healthy living. The depletion may be associated with an increasing number of side effects exhibited by statin patients – and relief from these side effects is not commonly known.

(Logo: http://photos.prnewswire.com/prnh/20120507/SF00557LOGO)  

In the past, statins have generally been considered to be safe, however, as the population of statin users continues to rapidly increase, statin studies continue to emerge showing that there is also a significant increase in the number of side effects, such as chronic fatigue and muscle pain. In fact, studies show that 10 to 20 percent of patients treated with statins complain of muscle symptoms and in rare instances use may result in serious muscle damage with myositis, inflammation and rhabdomyolysis. Even in the absence of clinically relevant muscle damage a significant number of patients experience an array of symptoms including muscle pain (myalgia), weakness, cramps and fatigue.

"Statins reduce cholesterol production effectively but not selectively – they also block the synthesis of Ubiquinol, a powerful lipid-soluble antioxidant found in every cell in the body that helps to protect the cardiovascular system from oxidative damage and an essential coenzyme required for cellular energy production," explains Dr. Robert Barry, Executive Director of Scientific Affairs at Kaneka Nutrients, the leading manufacturer of Ubiquinol supplements in the United States. The company reports that depletion of Ubiquinol can induce mitochondrial dysfunction by impairing oxidative phosphorylation, energy production and aerobic capacity. Ubiquinol depletion resulting from statin treatment may therefore impair muscle energy metabolism and contribute to the development of myopathy and muscle symptoms.  

Many statin patients are not informed of this sometimes severe side-effect. Statin-related symptoms can affect the quality of life and often result in multiple dose alterations, switching brands of statins and ultimately, non-compliance. Statin patients who take Ubiquinol as a supplement therapy will be replacing the loss of Ubiquinol in the body and giving back what the muscles need to perform.

Talk to your doctor about supplementing your diet with Ubiquinol, sold in most pharmacies and health food stores. Visit Ubiquinol.org to learn more.

About Kaneka Nutrients:
Ubiquinol is manufactured in the USA by Kaneka, the leader in premium CoQ10 ingredients worldwide. Ubiquinol helps sustain the body's natural energy, protect cells from damage, slow the aging process, and promote the overall health of the heart and other vital organs. It is the advanced active form of CoQ10 that is more easily utilized and absorbed in the body. Kaneka was the first company to successfully commercialize CoQ10 and Ubiquinol and has been the single largest supporter of research for more than 30 years. For more information and the latest clinical research on Ubiquinol, please visit www.ubiquinol.org.


'/>"/>
SOURCE Kaneka Nutrients
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Survey Finds At-Risk Consumers Interested in OTC Statin
4. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
5. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
6. Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
7. New Research Shows One in 200 People Born with DNA Mutation That Can Lead to Devastating, Often Fatal Disease
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
10. Seniors Can Be Heartened by New Study on Statins
11. New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):